Making efficacy visible with every image

Cut the wait, not corners. Reclaim control of your time and resources with Clario's fast, accurate medical imaging solutions for efficacy in oncology trials.

Try our survey to determine if Clario is right for you.

Jump to survey

With us, you're not just saving time – you're investing in progress

Imagine **reducing the industry-standard 39-day* database lock wait time to just 14 days or less for your oncology trial. This 64% time reduction equates to 600 saved hours,** providing opportunity for thorough data analysis, drug refinement, perfecting trial protocols and a chance for your team to catch their breath.

With Clario, it's not just about speed; it's about enabling efficacy and drawing on 50+ years of total experience. Our capacity to expedite the database lock is not an isolated proficiency, but **a testament to our wider operational, scientific and regulatory excellence honed over 1,700+ oncology trials, of which 100+ reached *regulatory approval.**

Get a free science consult

*According to Tufts Center for the Study of Drug Development

50+
indications

75%
of all oncology FDA approvals since 2012 were Clario supported

1,700+
total oncology trials

40+
different imaging criteria

What medical imaging solutions do you need?

> We need a CRO with a strong network and innovative strategies to aid in **patient recruitment and retention**.

> We need demonstrated expertise in **navigating regulations**, from the FDA to the EMA and beyond.

> The **quality and accuracy of our medical images** are paramount. We need a CRO with the technology and expertise to deliver on this.

With our comprehensive services, we've played a crucial role in 75% of in total oncology FDA approvals since 2012. Here's a snapshot of our accomplishments and offerings:

Regulatory approvals in over **120 countries**

30+ years of working with the FDA and EMA and key clinical research associations to establish core lab industry standards and imaging endpoints for clinical trials

Medical writing professionals driving Imaging Review Charter development alongside **internal and external experts**

With Image Redact-AI, our industry-leading clinical trial privacy redaction software that pairs AI-driven de-identification with **expert human oversight of a quality control (QC) team** to help you comply with 21 CFR Part 11, EU GDPR and other privacy regulations for images and videos

> We need **strong medical imaging expertise** for precise interpretation and analysis of oncology trial images.

> We're under competitive pressure to license to pharma or sell our drug. We want **complete services that cover all the essential endpoints**, including PROs.

> As a small biotech, we face resource and timeline challenges. We require **seamless integration and reliable solutions**.

> In our fast-paced trials, having **fast access to quality-assured imaging data** is crucial for making timely decisions.

> Our trials often require a range of imaging modalities. We need a CRO that's well-equipped to handle **MRI and CT scans to PET scans and more**.

> Our oncology trials demand a **global and flexible trial design** to accommodate the needs of our patients and the specifics of our drugs.

Could your trial benefit from a collaboration with our scientists?

Try this 10-second survey to find out.

Are you looking for a CRO that can support an adaptive trial design, responding quickly to changes in the trial due to interim analyses?

- YES
- NO

Are you need assistance in PRO on the selection and implementation of suitable PRO measures?

- YES
- NO

Does your trial involv patients or other pat additional considerat

- YES
- NO

Ready to evaluate potential CRO partners? Download this one-page checklist to help in your determination.

Download checklist

Frequently Asked Questions

Does Clario provide cost flexibility?

I'm concerned we won't receive the same level of personalized service as your bigger clients. Can you reassure us on this point?

Size doesn't dictate care at Clario. Every trial matters to us, big or small, because each contributes to better patient outcomes.

Yes, we're a large organization. However, this doesn't overshadow our attention to smaller clients or personalized service. Here's how our scale benefits biotech clients:

- **Efficiency from scale:** Our large organization brings tried-and-true processes from 50+ years and 21,000+ total trials, ensuring your trial won't be hampered by teething problems or trial-and-error strategies.
- **Broad expert network:** Our size allows us to maintain a diverse team of scientists and medical doctors across Medical Imaging, Cardiac Safety, eCOA, Precision Motion and Respiratory, which smaller organizations can't always afford to maintain. As a result, you'll have access to top-tier expertise, no matter how specific your needs.
- **Strong influence on regulatory bodies:** Our strong standing within the industry lends us significant influence on regulatory bodies like the FDA, EMA, NMPA and others.
- **Equal client support:** The fear of "taking a backseat" stems from the concern that larger clients might get more attention. But we treat every client with the highest level of support and service, regardless of size. With an average NPS score of 51, our project management teams are celebrated by our clients, both big and small.
- **Capacity to handle large, global projects:** If your trials expand or if you're planning a significant project from the get-go, our breadth means we have the capacity to handle it globally without compromising on the quality or speed of our service. Smaller vendors might struggle with scale-up, leading to delays or quality issues.

With us, you get the best of both worlds – the capabilities, global reach and resources of a big company, and the customer service and personalized solutions of a small one. Our size is not a hindrance, but rather an asset that helps us serve you better.

How can Clario ensure quality in the face of cost and time efficiency?

How can I be sure that Clario's solutions will be compatible with my trial's unique needs?

Can Clario support us not only in the initial stages but also in the long-term, given our growth plans?

What if our trial involves novel or complex imaging biomarkers? Does Clario have the capabilities to handle these?

Join us on Sept X 2023

Small paragraph with information about the webinar.

What you will learn:

- Look at how the new guidance can make TQT waivers more accessible for typical drugs
- Follow the journey of a hypothetical candidate leveraging early phase QT assessments
- Examine QT assessment for oncologics and the impact of the new guidance.

Register now





CLARIO. | American Cancer Society

Championing change in oncology clinical trials

Learn how in partnership with ACS, we're not just fighting cancer, we're changing how it's fought.

Find out more

Making efficacy visible with every image

Cut the wait, not corners. Reclaim control of your time and resources with Clario's fast, accurate medical imaging solutions for efficacy in oncology trials.

Try our survey to determine if Clario is right for you.

Jump to survey

With us, you're not just saving time – you're investing in progress

Imagine **reducing the industry-standard 39-day* database lock wait time to just 14 days or less for your oncology trial. This 64% time reduction equates to 600 saved hours,** providing opportunity for thorough data analysis, drug refinement, perfecting trial protocols and a chance for your team to catch their breath.

With Clario, it's not just about speed; it's about enabling efficacy and drawing on 50+ years of total experience. Our capacity to expedite the database lock is not an isolated proficiency, but **a testament to our wider operational, scientific and regulatory excellence honed over 1,700+ oncology trials, of which 100+ reached regulatory approval.**

Get a free science consult

*According to Tufts Center for the Study of Drug Development

50+
indications

75%
of all oncology FDA approvals since 2012 were Clario supported

1,700+
total oncology trials

40+
different imaging criteria

What medical imaging solutions do you need?

> We need a CRO with a strong network and innovative strategies to aid in **patient recruitment and retention**.

> We need demonstrated expertise in **navigating regulations**, from the FDA to the EMA and beyond.

> The **quality and accuracy of our medical images** are paramount. We need a CRO with the technology and expertise to deliver on this.

With our comprehensive services, we've played a crucial role in 75% of in total oncology FDA approvals since 2012. Here's a snapshot of our accomplishments and offerings:

Regulatory approvals in over **120 countries**

30+ years of working with the FDA and EMA and key clinical research associations to establish core lab industry standards and imaging endpoints for clinical trials

Medical writing professionals driving Imaging Review Charter development alongside **internal and external experts**

With Image Redact AI, our industry-leading clinical trial privacy redaction software that pairs AI-driven de-identification with **expert human oversight of a quality control (QC) team** to help you comply with 21 CFR Part 11, EU GDPR and other privacy regulations for images and videos

> We need **strong medical imaging expertise** for precise interpretation and analysis of oncology trial images.

> We're under competitive pressure to license to pharma or sell our drug. We want **complete services that cover all the essential endpoints**, including PROs.

> As a small biotech, we face resource and timeline challenges. We require **seamless integration and reliable solutions**.

> In our fast-paced trials, having **fast access to quality-assured imaging data** is crucial for making timely decisions.

> Our trials often require a range of imaging modalities. We need a CRO that's well-equipped to handle **MRI and CT scans to PET scans and more**.

> Our oncology trials demand a **global and flexible trial design** to accommodate the needs of our patients and the specifics of our drugs.

Could your trial benefit from a collaboration with our scientists?

Try this 10-second survey to find out.

Are you looking for a CRO that can support an adaptive trial design, responding quickly to changes in the trial due to interim analyses?

- YES
- NO

Are you need assistance in PRO on the selection and implementation of suitable PRO measures?

- YES
- NO

Does your trial involv patients or other pat additional considerat

- YES
- NO

Ready to evaluate potential CRO partners? Download this one-page checklist to help in your determination.

Download checklist

Frequently Asked Questions

Does Clario provide cost flexibility?

I'm concerned we won't receive the same level of personalized service as your bigger clients. Can you reassure us on this point?

Size doesn't dictate care at Clario. Every trial matters to us, big or small, because each contributes to better patient outcomes.

Yes, we're a large organization. However, this doesn't overshadow our attention to smaller clients or personalized service. Here's how our scale benefits biotech clients:

- **Efficiency from scale:** Our large organization brings tried-and-true processes from 50+ years and 21,000+ total trials, ensuring your trial won't be hampered by teething problems or trial-and-error strategies.
- **Broad expert network:** Our size allows us to maintain a diverse team of scientists and medical doctors across Medical Imaging, Cardiac Safety, eCOA, Precision Motion and Respiratory, which smaller organizations can't always afford to maintain. As a result, you'll have access to top-tier expertise, no matter how specific your needs.
- **Strong influence on regulatory bodies:** Our strong standing within the industry lends us significant influence on regulatory bodies like the FDA, EMA, NMPA and others.
- **Equal client support:** The fear of "taking a backseat" stems from the concern that larger clients might get more attention. But we treat every client with the highest level of support and service, regardless of size. With an average NPS score of 51, our project management teams are celebrated by our clients, both big and small.
- **Capacity to handle large, global projects:** If your trials expand or if you're planning a significant project from the get-go, our breadth means we have the capacity to handle it globally without compromising on the quality or speed of our service. Smaller vendors might struggle with scale-up, leading to delays or quality issues.

With us, you get the best of both worlds – the capabilities, global reach and resources of a big company, and the customer service and personalized solutions of a small one. Our size is not a hindrance, but rather an asset that helps us serve you better.

How can Clario ensure quality in the face of cost and time efficiency?

How can I be sure that Clario's solutions will be compatible with my trial's unique needs?

Can Clario support us not only in the initial stages but also in the long-term, given our growth plans?

What if our trial involves novel or complex imaging biomarkers? Does Clario have the capabilities to handle these?

Join us on Sept X 2023

Small paragraph with information about the webinar.

What you will learn:

- Look at how the new guidance can make TQT waivers more accessible for typical drugs
- Follow the journey of two oncology candidates leveraging early phase QT assessments
- Examine QT assessment for oncologics and the impact of the new guidance.

Register now



CLARIO. | American Cancer Society

Championing change in oncology clinical trials

Learn how in partnership with ACS, we're not just fighting cancer, we're changing how it's fought.

Find out more